Security key
G9835J103
- Security type / class
- Equity / *W EXP 08/28/203
- Total 13F shares
- 5,354,063
- Total 13F value
- $3,475,499
- Share change
- +183,567
- SEC-reported price per share
- $0.65
- Number of holders
- 8
- Value change
- +$110,741
- Number of buys
- 3
- Number of sells
- 4
Report period
Q1 2026
Institutions
8
Top holders
8
YDESW full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
YD Bio Ltd SEC filings
YD Bio Ltd company facts
Broader feeds
Reporting periods
Holder history for CUSIP G9835J103
Recent filing periods:
Ownership snapshot
Top reported holders of YDESW - YD Bio Ltd - *W EXP 08/28/203 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ethan Shen PhD
Disclosed value leader
Ethan Shen PhD
Comparable rows
8/15
Latest evidence
18 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 77%
7 rows are not safely comparable across share classes.
13D/G row: Ethan Shen PhD
Showing 1-6 of 15 holder rows.
Quick read
Ethan Shen PhD leads the comparable SEC ownership view at 77%.
8 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ethan Shen PhD's linked filing trail.
Comparable ownership
Top 5
Ethan Shen PhD
77%
Bo-Xiang Zhang
0.04%
GEODE CAPITAL MANAGEMENT, LLC
0.08%
CITADEL ADVISORS LLC
0.02%
WOLVERINE ASSET MANAGEMENT LLC
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ethan Shen PhD |
13D/G
3/4/5
Ethan Shen · CEO, Director
|
77%
|
$663,552,584
54,345,011 shares
|
$0 | 17 Feb 2026 |
| Bo-Xiang Zhang |
3/4/5
Chief Medical Officer, Director
|
0.04%
|
$379,608
31,141 shares
|
— | 18 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.08%
|
$711,444
58,363 shares
|
— | 31 Dec 2025 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.02%
|
$140,782
11,549 shares
|
— | 31 Dec 2025 |
| WOLVERINE ASSET MANAGEMENT LLC |
13F
Company
|
0%
|
$30,670
2,516 shares
|
— | 31 Dec 2025 |
| CITIGROUP INC |
13F
Company
|
0%
|
$20,833
1,709 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
8
Shares
5,354,063
Rows available
8
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
11
Q1 2026 holders
8
Holder diff
-3
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend